SCHEMBL12427360

SCHEMBL12427360

COc1cc(C(=O)NCCCN2CCN(C)CC2)ccc1N

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.64
CYP2C9 P11712 1/20 0.64
HTR4 Q13639 1/20 0.63
SLC29A1 Q99808 1/20 0.61
MAPT P10636 2/20 0.58
HTR1A P08908 2/20 0.57
ADRA2A P08913 2/20 0.57
KMT2A Q03164 2/20 0.56
RAD52 P43351 1/20 0.56
DRD2 P14416 5/20 0.56
DRD3 P35462 4/20 0.56
DRD4 P21917 3/20 0.56
TLR9 Q9NR96 1/20 0.55
TLR8 Q9NR97 1/20 0.55
TLR7 Q9NYK1 1/20 0.55
ALDH1A1 P00352 2/20 0.54
KDM4E B2RXH2 1/20 0.54
HPGD P15428 1/20 0.54
MAP3K7 O43318 1/20 0.54
SLC6A2 P23975 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12426361 0.93 KMT2A (0.65) CYP2D6CYP2C9HTR4SLC29A1HTR1A
SCHEMBL13575609 0.92 CYP2D6 (0.63) CYP2D6CYP2C9HTR4SLC29A1MAPT
SCHEMBL12427422 0.92 SLC29A1 (0.66) CYP2D6CYP2C9HTR4SLC29A1MAPT
SCHEMBL12426657 0.91 SLC29A1 (0.65) CYP2D6CYP2C9HTR4SLC29A1MAPT
SCHEMBL12427425 0.90 CYP2D6 (0.63) CYP2D6CYP2C9HTR4SLC29A1MAPT
SCHEMBL12426322 0.89 CYP2C9 (0.82) CYP2D6CYP2C9HTR4SLC29A1KMT2A
SCHEMBL12426329 0.88 HTR4 (0.68) CYP2D6CYP2C9HTR4SLC29A1MAPT
SCHEMBL2949573 0.87 RAD52 (0.61) CYP2D6CYP2C9MAPTKMT2ARAD52
SCHEMBL13575485 0.86 CYP2D6 (0.56) CYP2D6CYP2C9HTR4SLC29A1MAPT
SCHEMBL5924297 0.85 RAD52 (0.59) CYP2D6CYP2C9MAPTKMT2ARAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003785-B2 Halo-substituted pyrimidodiazepines TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) 2011-08-23 US disclosed
EP-1983987-B1 DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2010-09-01 EP disclosed
US-20090318408-A1 HALO-SUBSTITUTED PYRIMIDODIAZEPINES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-24 US disclosed
WO-2009153197-A1 HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-12-23 WO disclosed
WO-2007095188-A2 DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318408-A1 HALO-SUBSTITUTED PYRIMIDODIAZEPINES PLK1, CCNI, CDK1 CYP2D6 2081/4885CYP2C9 3029/4885HTR4 2822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.